Q-omics provides the consensus-scored CAVIN3 profile across patient tissues and cancer cell-line models. CAVIN3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CAVIN3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CAVIN3 protein abundance shows 32,482 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where CAVIN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAVIN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAVIN3 survival associations across molecular data types. CAVIN3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAVIN3 RNA expression–survival associations across cancer types. High CAVIN3 expression shows unfavorable associations in UVM, LUSC, LUAD, LGG and CESC, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CAVIN3 RNA expression.
This table summarizes CAVIN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CAVIN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAVIN3 shows lower tumor expression in BLCA, KICH and UCEC and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher CAVIN3 RNA expression in tumor versus normal tissue (log2 FC = +2.454, t-test p < 0.001).
This table shows molecular features associated with CAVIN3 in patient tissues and cancer cell lines. In patient samples, CAVIN3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAVIN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
